Rest Therapeutics’ investigational PTSD therapy, RST-101, cleared an early regulatory milestone as the U.S. FDA accepted its IND application. The acceptance supports the company’s plan to begin early clinical evaluation of a candidate targeted at early treatment of post-traumatic stress disorder. For developers, IND acceptance is typically the threshold for moving from preclinical work into human studies, enabling protocol approval and patient enrollment under FDA oversight. The decision highlights continued interest in novel, early-intervention approaches for psychiatric conditions with large unmet need.